Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2091732 | 0.95 | TDP1 (0.66) | TDP1L3MBTL1CYP2A6HRH1CHRNA7 | |
| SCHEMBL2092004 | 0.93 | TDP1 (0.64) | TDP1L3MBTL1CYP2A6HRH1CHRNA7 | |
| SCHEMBL273379 | 0.89 | CHRNA7 (0.57) | TDP1L3MBTL1CYP2A6HRH1CHRNA7 | |
| SCHEMBL14524266 | 0.82 | TDP1 (0.64) | TDP1L3MBTL1CYP2A6HRH1CHRNA7 | |
| SCHEMBL29485677 | 0.82 | CYP2A6 (0.76) | TDP1L3MBTL1CYP2A6HRH1CHRNA7 | |
| SCHEMBL29485675 | 0.82 | TDP1 (0.80) | TDP1L3MBTL1CYP2A6HRH1CHRNA7 | |
| SCHEMBL724788 | 0.82 | TDP1 (0.80) | TDP1L3MBTL1CYP2A6HRH1CHRNA7 | |
| SCHEMBL2843094 | 0.82 | CYP2A6 (0.76) | TDP1L3MBTL1CYP2A6HRH1CHRNA7 | |
| SCHEMBL14499025 | 0.81 | TDP1 (0.57) | TDP1L3MBTL1CYP2A6HRH1CHRNA7 | |
| SCHEMBL14498994 | 0.81 | L3MBTL1 (0.57) | TDP1L3MBTL1CYP2A6HRH1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723744-B1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-23 | — | — | EP | disclosed |
| CN-102596961-B | Imidazo [1,2-b] pyridazine derivatives and the purposes as PDE10 inhibitor thereof | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-12-02 | — | — | CN | disclosed |
| US-8673908-B2 | Kynurenine production inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8673908-B2 | Kynurenine production inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2374802-A1 | KYNURENINE PRODUCTION INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYOWA KIRIN CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYOWA KIRIN CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| WO-2010053182-A1 | KYNURENINE PRODUCTION INHIBITOR | 協和発酵キリン株式会社 (JP) | 2010-05-14 | — | — | WO | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | TDP1 1197/4885L3MBTL1 4124/4885CYP2A6 3068/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | TDP1 326/4885L3MBTL1 2776/4885CYP2A6 3523/4885 |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYNU, KMO, IDO1 | TDP1 2717/4885L3MBTL1 631/4885CYP2A6 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.